跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,372 条关于
“uHCC”
全部
1,372
临床试验
1,307
药物
6
机构
0
资讯
59
2年前
STRIDE Regimen Shows Unprecedented 5-Year Survival in Unresectable Hepatocellular Carcinoma
去年
Conversion Therapy Shows Promise in Unresectable Hepatocellular Carcinoma
去年
FDA Accepts Resubmission of Rivoceranib and Camrelizumab for Liver Cancer
去年
FDA Accepts Rivoceranib and Camrelizumab Combination for Liver Cancer
去年
FDA Accepts Resubmission of NDA for Rivoceranib and Camrelizumab in Unresectable Hepatocellular Carcinoma
去年
Apatinib Plus DEB-TACE Improves Outcomes in Unresectable Hepatocellular Carcinoma
3年前
FDA Accepts NDA for Rivoceranib and Camrelizumab Combination in Unresectable Hepatocellular Carcinoma
去年
STRIDE Immunotherapy Achieves Unprecedented 19.6% Five-Year Survival Rate in Advanced Liver Cancer
3年前
Elevar Therapeutics Seeks FDA Approval for Rivoceranib and Camrelizumab Combination in Unresectable Hepatocellular Carcinoma
去年
Envafolimab, Lenvatinib, and TACE Combination Shows Promise in Unresectable HCC
第 1 页,共 6 页
上一页
下一页